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Background: Copy number variations (CNVs) are the major type of structural variation in the human genome, and
are more common than DNA sequence variations in populations. CNVs are important factors for human genetic
and phenotypic diversity. Many CNVs have been associated with either resistance to diseases or identified as the
cause of diseases. Currently little is known about the role of CNVs in causing deafness. CNVs are currently not
analyzed by conventional genetic analysis methods to study deafness. Here we detected both DNA sequence
variations and CNVs affecting 80 genes known to be required for normal hearing.
Methods: Coding regions of the deafness genes were captured by a hybridization-based method and processed
through the standard next-generation sequencing (NGS) protocol using the Illumina platform. Samples hybridized
together in the same reaction were analyzed to obtain CNVs. A read depth based method was used to measure
CNVs at the resolution of a single exon. Results were validated by the quantitative PCR (qPCR) based method.
Results: Among 79 sporadic cases clinically diagnosed with sensorineural hearing loss, we identified
previously-reported disease-causing sequence mutations in 16 cases. In addition, we identified a total of 97 CNVs
(72 CNV gains and 25 CNV losses) in 27 deafness genes. The CNVs included homozygous deletions which may directly
give rise to deleterious effects on protein functions known to be essential for hearing, as well as heterozygous deletions
and CNV gains compounded with sequence mutations in deafness genes that could potentially harm gene functions.
Conclusions: We studied how CNVs in known deafness genes may result in deafness. Data provided here served as a
basis to explain how CNVs disrupt normal functions of deafness genes. These results may significantly expand our
understanding about how various types of genetic mutations cause deafness in humans.
Keywords: Genetic deafness, Copy number variations, Sequence mutations, Next-generation sequencing, Deafness
gene panel, HearingBackground
Hearing impairment is one of the most common human
disabilities. Multiple factors, including ototoxic drug
usage, noise exposure, and genetic mutations can cause
hearing loss. The majority of human hearing loss cases
(~70%), however, are attributed to genetic factors [1].
Large numbers of studies have identified many deafness
genes whose functions are essential for normal hearing* Correspondence: hwli@shmu.edu.cn; xlin2@emory.edu
†Equal contributors
1Department of Otolaryngology, Eye & ENT Hospital, Fudan University, #83
Fenyang Road, Shanghai 200031, P.R China
2Department of Otolaryngology, Emory University School of Medicine, 615
Michael Street, Atlanta, GA 30322-3030, USA
© 2014 Ji et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[2] (Additional file 1: Table S1). Deleterious DNA se-
quence mutations in these genes lead to inherited deaf-
ness. In most cases a single monogenic mutation is
sufficient to result in severe hearing loss [2,3]. The deaf-
ness genotype and phenotype relations are usually tightly
defined [1], making information about genetic mutations
valuable in providing essential diagnostic and prognostic
information. The diagnostic information could be used
in the management and treatment of hearing loss as it
identifies the root cause of deafness.
Mutations that cause congenital deafness involve a
highly diverse group of genes [4]. Traditionally, genetic
diagnosis of deafness genes is done by Sanger sequencinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the NGS approach have been developed to sequence
multiple deafness genes in one test, which have greatly
increased the efficiency in screening for large numbers
of mutations in deafness genes for diagnostic purposes
as well as for finding new deafness genes [3,5]. How-
ever, NGS screening of sequence mutations in multiple
genes are usually limited to detecting single nucleotide
variations and small insertions and deletions (InDels)
usually smaller than 20 base pairs (bps). Copy number
variations (CNVs) are copy number gains or losses of
DNA segments ranging from 100 to more than a mil-
lion base pairs in length. CNVs are important factors
for human genetic and phenotypic diversity [6]. CNVs
are currently not analyzed by conventional data analysis
methods in the NGS approach to study deafness. It is
estimated that up to 29% of the genomes of unrelated
individuals may differ in copy numbers [6]. Many CNVs
have been associated with either resistance to diseases
or identified as the cause of diseases [6]. However, con-
tribution of CNVs in genetic deafness is unclear. Here
we have used a NGS-based approach to investigate novel
mechanisms of combined sequence variations and CNVs
in 80 deafness genes that cause inherited deafness.
Methods
Patient history and physical/laboratory examinations
Patients (N = 79) were recruited from outpatients who
visited the Eye & ENT Hospital of Fudan University. All
participants were informed about the scope and require-
ments of the study, and signed the patient consent form
approved by the ethics committee of Fudan University.
They were all diagnosed with sensorineural hearing loss.
Cases caused by trauma, use of ototoxic drugs, and otitis
media were excluded from this study. Patients with
history of meningitis and maternal Cytomegalovirus
(CMV), if they are known, were also excluded. Patient
history information included the time of onset of hear-
ing loss, and the degree of hearing loss, classified as
either mild (21–40 dB, N = 14), moderate (41–70 dB,
N = 35), severe (71–90 dB, N = 11), or profound (>90 dB,
N = 19). Other pertinent facts included family history of
deafness, pregnancy and labor history, general health
conditions, and chronic diseases that might affect hearing
such as type 2 diabetes mellitus and hypertension. Gen-
eral physical examinations were conducted with particu-
lar emphasis on examination of the ears, intellectual
ability, syndromic features of congenital deafness (such
as the presence of white hair at the forehead, hyperpig-
mentation, heterochromia iridis, dystopia canthorum,
and broadening of the nasal root). Laboratory tests in-
cluded pure tone audiometry, acoustic immittance, audi-
tory brainstem responses, multiple-frequency auditory
steady-state responses, and distortion product otoacousticemission (DPOAE). Computed tomography and magnetic
resonance imaging were conducted for some patients for
whom it was considered clinically necessary.
Protocols for DNA extraction, PCR-based Sanger sequencing
for detecting mutations in validation tests
Genomic DNA (gDNA) was isolated from 3–5 ml of
blood, according to the standard protocol provided by
the manufacturer (Qiagen, Valencia, CA). The quality of
gDNA was assured by examining the optical density
ratio (260/280 ratio) and by checking the results via
gel electrophoresis imaging. The coding exon of GJB2
(exon2) was amplified by polymerase chain reactions
(PCR) using two specific primers: F (Fn1): 5’ TTGG
TGTTTGCTCAGGAAGA 3’, R (R3C): 5’ GGCCTA
CAGGGGTTTCAAAT 3. The reaction was performed
in a volume of 25 μl containing 1.5 mM MgCl2 250 mM
dNTPs, 1 mM of each primer, 100 ng of genomic DNA,
and 1.25 U of rTaqDNA polymerase with an initial
denaturing step at 95.8°C for 12 min, followed by 35 cy-
cles at 94.8°C for 45 s, 60.8°C for 1 min, 72.8°C for
1.20 min, and a final elongation at 72.8°C for 7 min. Pre-
dicted amplicon sizes were confirmed by agarose gel
electrophoresis. Mutations in GJB2 were examined by
the standard Sanger sequencing method by a commer-
cial source (Beckman Coulter Genomics, Danvers, MA).
NGS protocol and data analysis
High-molecular weight gDNA (5 μg) was fragmented
ultrasonically with the Covaris E210 DNA shearing in-
strument (Covaris Inc., Woburn, MA) to an average size
of 300 bps for subsequent construction of Illumina NGS
libraries. The Covaris protocol is set at 3 minutes total
duration, duty cycle 10%, intensity 5, and 200 cycles per
burst. Fragmented gDNA libraries for sequencing on the
Illumina platform (HiSeq2000) were prepared with the
NEBNext™ DNA Sample Prep Master Mix set (E6040,
NEB Biolab, Ipswich, MA). End repair of DNA frag-
ments, addition of a 3’ adenine (A), adaptor ligation, and
reaction clean-up were carried out following the manu-
facturer’s protocol. gDNA libraries were cleaned and
size selected using the AMPure DNA Purification kit
(Beckman Agencourt, Danvers, MA). The ligated prod-
uct (20 ng) was amplified for 14 PCR cycles with Illumina
PCR primers InPE1.0 and indexing primer following the
manufacturer’s instructions. The PCR products were puri-
fied again with QIAquick MinElute column and eluted into
50 μl of hybridization buffer (HB, Roche NimbleGen,
Madison, WI).
Targeted capture of deafness genes (Additional file 1:
Table S1) and the examination for the enrichment of these
genes by quantitative PCR (qPCR) were carried out by pro-
tocols described in our published paper [7]. Systematic
comparison of different tools in population-scale genomic
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methods used in identifying genomic regions ascertained,
size-range and breakpoint [8]. Since only partially-
overlapping CNVs are identified using different methods,
some studies used as many as 36 CNV call-sets to help im-
prove the accuracy of finding high-confidence CNVs [8].
In our study, FASTQ data files generated after sequencing
with the Illumina HiSeq2000 were processed using four
independent bioinformatic data processing pipelines, since
the use of multiple independent bioinformatic pipelines
help improve accuracy in finding high-confidence CNVs
[9]. These bioinformatic platforms are:
(1)A web-based open source platform called Galaxy
(https://usegalaxy.org/), which runs on a local Linux
server. The tools we used on Galaxy Platform were:
(a) BWA (ver. 0.7.4), to generate SAM (Sequence
Align/Map) files; (b) Samtools (ver.0.1.19), which
were used to transform Binary SAM into BAM and
were sorted with samtools; (c) Picard (ver. 1.79), this
was used to remove PCR duplicates in the sorted
BAM files; (d) GenomeAnalysisTK-1.6 (GATK-1.6).
The duplicate-removed BAM files were used as
inputs of GATK-1.6 for InDel re-alignment and base
quality recalibration using known InDels from
dbSNP137 and the 1000 Genome project. Target
region coverage and VCF (Variant Calling Format)
files of SNP/InDel calling were generated by GATK,
based on processed BAM files.
(2)A software package developed at the Broad Institute
called Genome Analysis Toolkit (GATK) (http://
www.broadinstitute.org/gatk/).
(3)A paid commercial bioinformatic analysis platform
(www.dnanexus.com).
(4)A proprietary bioinformatic processing pipeline
called NGSeq, developed in-house specifically for
analyzing mutations in targeted deafness genes.
The variation and CNV results presented here are con-
sensus results of the four bioinformatic pipelines. The con-
sensus rates among different platforms were high, with the
lowest being 94.5% between the GATK and Galaxy pipe-
lines. Sequencing results obtained by the NGS method for
the coding region of the GJB2 gene were compared to
those obtained by the Sanger method (N = 8) for validation
purposes. A high percentage (99.2%) of detected sequence
variations (SNPs) in the GJB2 gene as identified by the two
methods agreed with each other. All samples processed in
this project had an on-target average coverage of greater
than 100 (Additional file 1: Table S1). Distribution of aver-
age coverage (n = 10) at 0x, 1x, 10x & 20x was 1.1 ± 0.5,
4.8 ± 1.1, 5.6 ± 1.9 and 11.2 ± 2.9, respectively. After con-
trolling for data quality (coverage ≥20 and Phred-like qual-
ity score ≥30), we obtained the VCF reports for the codingregions and the exon-intron boundaries of the tar-
geted deafness genes (Additional file 1: Table S1).
Variations contained in VCF reports were filtered by
a custom knowledge database in order to identify candi-
date disease-causing mutations. Information in this data-
base was collected from the following sources: (1) Human
Genome Mutation Database (HGMD); (2) data from un-
published mutation and normal hearing control results
obtained in the authors’ lab; (3) data made from consensus
predications of both PolyPhen and Shift bioinformatic
algorithms [10]. Variants with high population allele fre-
quencies (>0.02), as reported by data collected from the
1000 genome project, were filtered out. The identified var-
iations were classified into nine categories (see Additional
file 2: Table S2). Mutations in these categories can be
defined as disease-causing, highly likely to be disease-
causing, predicted but unconfirmed to be disease-causing,
carrier of mutations, and novel mutations with low popu-
lation allele frequencies (less than 0.005) of unknown
significance.
In the hybridization step for capturing the targeted deaf-
ness genes, we normally hybridized 20–30 samples to-
gether. Samples were differentiated by different barcodes.
In-house generated cDNA capture probes with lengths
ranging from 100 to ~5000 bps were used. Biotinylated
probes were hybridized overnight with fragmented gen-
omic DNA (gDNA) at 47°C in a thermocycler (Bio-Rad
T100, Hercules, CA). Captured gDNA fragments were
enriched using streptavidin dynabeads (Beckman Coulter,
Brea, CA). For targeted NGS projects, on-target coverage
after the capturing step is a more appropriate index for de-
scribing the quality of sequencing, not the number of
overall reads. The average depth of coverage for each exon
of targeted deafness genes was used in the calculation of
CNVs. Compared to previous methods used to detect
CNVs from whole human genome or exome NGS data
[9], this is a novel method used to specifically detect CNVs
from NGS data obtained in a disease (e.g., deafness) panel.
The mean coverage can be affected by CNVs, the relative
quantity of DNA in each sample loaded for hybridization,
and the experimental conditions. By analyzing the CNVs
only for samples that were hybridized together, we could
control the level of variation introduced by the experimen-
tal conditions. The relative quantity of loading DNA for
each sample was normalized by the summed total of the
average depth of coverage (Sd), which yielded a normalized
average depth of coverage Nadc = (depth of coverage of
specific exon)/Sd. The ratio of CNVs (RCNV) for each exon




average Nadcof all other samples in the
same hybridization for this exon

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the ratio should be close to one. Heterozygous and
complete deletions would result in a ratio close to 0.5
and 0, respectively. CNV gains would yield ratios of 1.5
or larger (illustrated in Figure 1). The resolution of our
method used to detect CNVs is the size of a single
exon as determined by comparing the average depth of
coverage for each exon. Bioinformatic analysis of the
gene structure showed that the average exon size for
the 80 deafness genes (Additional file 1: Table S1) is
4491 bps.
In order to validate our NGS-based approach in iden-
tifying the CNVs, we randomly selected 15 putative
CNVs and examined these CNVs again using the inde-
pendent qPCR approach. A commercially-available CNV
test kit based on SYBR green chemistry (DyNAmo
ColorFlash SYBR Green qPCR Kit, Thermo Scientific
Inc., Pittsburgh PA) was used. A house-keeping gene
(GAPDH) was used as a reference for the qPCR quantifi-
cation. Primers for amplifying selected genes and refer-
ence genes (Additional file 3: Table S4) were designed by
Primer3 (http://frodo.wi.mit.edu). Triplicate qPCR reac-
tions were conducted for each sample, each using a reac-
tion volume of 25 μl. The relative abundance of genomic
DNA in samples was calculated by looking at the differ-
ences in the cycle numbers obtained in the linear increas-
ing phase, using the following steps:Figure 1 Typical examples of CNVs detected in patient samples. The x-a
genes as listed in the Additional file 1: Table S1. The y-axis gives the RCNV ratio
exon 1 of the DIAPH1 gene. (B) This example shows a heterozygous deletion
8 of DIAPH1 gene. The ratio of exon 8 of DIAPH1 gene was close to 2, suggest
to the normal copy number. (D) This example shows heterozygous deletion c
and span at least 48 k bps.1) Calculating threshold cycle (Ct) differences between
the target gene and the reference gene
ΔCt calibratorð Þ ¼ Ct target; calibratorð Þ–Ct reference; calibratorð Þ
ΔCt testð Þ ¼ Ct target; testð Þ–Ct reference; testð Þ
2) Normalizing ΔCt of the test samples to the ΔCt of
the calibrator:
ΔΔCt ¼ ΔCt testð Þ–ΔCt calibratorð Þ
3) Calculating the CNV ratio using following formula:
CNV ratio = 2− ΔΔCt
Results
Analysis of DNA sequence variations and deafness
mutations by the NGS approach
In the 79 sporadic cases of patients clinically diagnosed
with sensorineural hearing loss, we were able to identify
16 patients with previously-reported pathogenic muta-
tions (Category I as defined in the Additional file 2:
Table S2) and 5 more with novel likely-pathogenic muta-
tions (Category III). Details on the DNA sequence muta-
tions we found are given in Table 1. In addition, wexis is the exon location sequentially arranged for the targeted deafness
calculated for CNVs. (A) An example of homozygous deletion of the
of the exon 20 of the OTOA gene. (C) An example of a CNV gain of exon
ing that the DNA segment containing this exon was doubled compared
overing two adjacent genes, STRC and CATSPER2 on Chromosome 15
Table 1 Previously-reported and likely pathogenic deafness mutations found in 79 patient samples examined in this study
Category # of
occurrence
SampleID Gene name Position on Chr Mutation
Category I 16 Ot3271 GJB2 Chr13: 20763612 C > T NM_004004:exon2: c. G109A: p. V37I
Ot3275 WFS1 Chr4: 6303680 A > G NM_001145853:exon8: c. A2158G: p. I720V,
NM_006005:exon8: c. A2158G: p. I720V
Ot3212 GJB2 Chr13: 20763486 del G NM_004004:exon2: c.235delC: p. L79fs
Ot3213 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Ot3227 GJB2 Chr13: 20763612 C > T NM_004004:exon2: c. G109A: p. V37I
Ot3230 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Ot3241 GJB2 Chr13: 20763612 C > T NM_004004:exon2: c. G109A: p. V37I
Ot3242 GJB2 Chr13: 20763612 C > T NM_004004:exon2: c. G109A: p. V37I
Ot3252 GJB2 Chr13: 20763612 C > T NM_004004:exon2: c. G109A: p. V37I
Ot3255 GJB2 Chr13: 20763486 del G NM_004004:exon2: c.235delC: p. L79fs
Ot3256 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Ot3258 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Ot3260 GJB2 Chr13: 20763486 del G NM_004004:exon2: c.235delC: p. L79fs
Ot3266 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Ot3276 GJB2 Chr13: 20763486 del G NM_004004:exon2: c.235delC: p. L79fs
Ot3284 SLC26A4 Chr7: 107323898 A > G NM_000441:exon8: c.919-2A > G
Category III 5 Ot3226 DSPP Chr4: 88537078 ins CGATAGCAG NM_014208:exon5: c.3264_3265insCGATAGCAG:p.
S1088delinsSRX




Ot3256 DSPP Chr4: 88537078 ins CGATAGCAG NM_014208:exon5: c.3264_3265insCGATAGCAG:p.
S1088delinsSRX
Ot3266 DSPP Chr4: 88537078 ins CGATAGCGG NM_014208:exon5: c.3264_3265insCGATAGCGG:p.
S1088delinsSRX
Ot3270 DSPP Chr4: 88537078 ins CGATAGCAA NM_014208:exon5: c.3264_3265insCGATAGCAA:p.
S1088delinsSRX
Category V 1 Ot3209 ESRRB Chr14: 76905712 A > G NM_004452:exon4: c. A16G: p. R6G
Category VII 7 Ot3217 DSPP Chr4: 88537088 A > G NM_014208:exon5: c. A3274G: p. N1092D
Ot3242 COCH Chr14: 31358873 A > G NM_001135058:exon11: c. A1529G: p. K510R,
NM_004086:exon12: c. A1529G: p. K510R
Ot3260 DSPP Chr4: 88537088 A > G NM_014208:exon5: c. A3274G: p. N1092D
Ot3268 MYO6 Chr6: 76576249 A > G NM_004999:exon17: c. A1681G: p. R561G
Ot3270 DSPP Chr4: 88537088 A > G NM_014208:exon5: c. A3274G: p. N1092D
Ot3284 SOX2 Chr3: 181430197 A > G NM_003106:exon1: c. A49G: p. T17A
Ot3284 DSPP Chr4: 88537088 A > G NM_014208:exon5: c. A3274G: p. N1092D
The definition of each category is given in the Additional file 2: Table S2.
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predications independently agreed upon by both SIFT
and PolyPhen bioinformatic algorithms [10,11]. The two
algorithms both predicted these mutations as damaging
or probably damaging to protein functions of deafness
genes known to be essential for hearing (Additional file 1:
Table S1).
We identified many well-established deafness muta-
tions (e.g., GJB2 c.235delC, GJB2 p.V37I, SLC26A4c.919-2A >G [12], as well as previously un-reported novel
mutations (e.g., DSPP c.3264_3265insCGATAGCGG,
p.S1088delinsSRX) which we predict to be deleterious
to protein functioning. The predictions were based on
the presence of frameshift or premature stop codon mu-
tations, which disrupt the function of genes known to be
essential for hearing [13]. In summary, depending on the
criteria used, the genetic basis of 27-37% of the sporadic
cases of sensorineural hearing loss was likely attributed
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common deafness genes found in these patients were (in
the order of occurrence, from high to low): GJB2, DSPP,
SLC26A4, COCH, ESRRB, MYO6, SOX2, TMPRSS3 and
WFS1.
CNVs found by the NGS approach and validation results
by qPCR
Among the 80 deafness genes (total of 1253 exons) ana-
lyzed from the 79 patient samples, we identified a total
of 97 CNVs. These included 72 CNV gains and 25 CNV
losses (details are given in the Table 2 and Additional
file 4: Table S5). Figure 1 gives examples of the CNV
losses (Figure 1, A, B&D) and gains (Figure 1C) we de-
tected. The x-axis is the exon location sequentially ar-
ranged for the deafness genes listed in the Additional
file 1: Table S1. The sequential number, corresponding
exon number, and gene name can be found in Additional
file 1: Table S1. The y-axis in Figure 1 is the ratio of CNVs
(RCNV), as calculated by the formula given in the Methods
section. Samples with normal copy number (N = 2) at the
targeted exon location would give a ratio near one. The
average ratio and range of standard deviation for each
exon of deafness gene are given by the box plot in the
graph (Figure 1). Figure 1A shows an example of a homo-
zygous deletion of the exon 1 of the DIAPH1 gene, which
could directly disrupt gene function. Figure 1 B & D shows
examples of heterozygous deletions. While the deletion
shown in Figure 1B affected only one exon (exon 20 of the
OTOA gene), the example shown in Figure 1D is a much
larger CNV deletion that affected two adjacent genes
(STRC and CATSPER2 on the Chromosome 15) and spans
at least 48 k bps. The example in Figure 1C shows a CNV
gain. The ratio of exon 8 of the DIAPH1 gene was close
to 2, suggesting that the DNA segment containing this
exon was doubled compared to the normal copy number.
Among the 79 patients we studied, the total number
of deafness genes affected by CNVs is twenty seven.
Among these 27, only five have corresponding pseudo-
genes. We detected the most number of CNVs on the
DIAPH1 gene, which is located on Chromosome 5.
Other affected deafness genes and the frequency of oc-
currence for each gene are given in the Table 3. Most
(approximately 97.6%) of the CNVs we identified affectedTable 2 Types of CNVs found in the 79 patient samples and t
Types of CNV Number of occurrence Po
Homozygous deletion (copy# ratio = 0) 4 Hom
Heterozygous deletion (copy# ratio = 0.5) 21 He
CNV increase with copy# ratio = 1.5 27
CNV increase with copy# ratio = 2 31
CNV increase with copy# ratio > 2 14only one exon. CNV identifications made using the NGS
approach were verified independently using the qPCR
method. Among 15 randomly selected CNVs, we found
that qPCR confirmed most (14 out of 15) of the CNVs
found by the NGS method (Additional file 5: Table S3),
therefore suggesting that the ratios derived from the aver-
age read depth of the NGS data provided a reliable esti-
mate of the CNVs in deafness genes.
Combined sequence variation and CNV analysis for the
cause of genetic deafness
Results presented in Table 1 show that, under the most
relaxed criteria, we could only detect pathogenic genetic
mutations in 29 of the 79 samples. We found another 20
patients who only showed CNVs without any point mu-
tations. Four of the patients (patient_ID: J246, J256,
J267, J319) carried homozygous CNV deletions that may
directly disrupt the functions of deafness genes. We also
found 12 patients to be carriers of deafness muta-
tions (belonging to the categories II or IV as defined
in Additional file 2: Table S2), who also bear CNVs
(Additional file 6: Table S6). One patient (ot3285) had a
heterozygous deafness mutation and a copy number re-
duction in the same gene (GJB3, Additional file 4:
Table S5). Since GJB3 has only one coding exon, this
combination may potentially result in compounded ef-
fects which cause disruption of GJB3 protein functions,
leading to deafness. The other 11 carriers had CNVs
affecting deafness genes different from those affected by
DNA sequence mutations, and the significance of such
combinations is currently unknown. Overall, combined
sequence variation and CNV analysis increased the detec-
tion rate from 36.7% (29/79) to 43.0% (34/79) among 79
sporadic patients clinically diagnosed with sensorineural
hearing loss.
Discussion
Genetic tests performed in the past, whether referring
to the traditional Sanger method or the newer NGS
method, only detect DNA sequence point substitutions
and small InDel mutations (usually less 20 bps) [4]. These
types of mutations have been well established as the
major cause of congenital deafness. With the availability
of genome-wide sequencing data and other genotypingheir predicted consequences in causing deafness
ssible zygosity Disease-causing?
ozygous (Hom) Yes
terozygous (Het) Possible when combined with sequence mutation(s)
Heterozygous Possible when combined with sequence mutation(s)
Het/Hom Possible
Het/Hom Possible
Table 3 The CNVs and the rank of occurrences found in
targeted deafness genes among the 79 patient samples
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hybridization (aCGH arrays)), large numbers of struc-
tural variations, including CNVs (e.g., >38,000 CNVs
found in segments >100 bp in size), balanced inversions,
and translocations have been reported [6]. In terms of
total bps involved, the incidence of structural variations
is estimated to be much higher than that of SNPs in pop-
ulations [14]. The contribution of CNVs to genetic deaf-
ness only begins to be revealed recently in a few papers
that have addressed this specific topic [15,16]. We have
evaluated the impact of CNVs in 80 targeted deafness
genes (Additional file 1: Table S1) on inherited hearing
loss. We performed a combined analysis of DNA se-
quence mutations and CNVs to assess how protein func-
tions known to be essential for hearing may be disrupted.
We were able to identify 21 out of 79 patients bearingdisease-causing sequence mutations (Table 1). For the
remaining samples where we could not find sequence
mutations directly responsible for deafness, we identified
an additional four patients bearing homozygous CNV
deletions which may directly disrupt gene function. Add-
itionally, we found another patient bearing both sequence
and CNV mutations in the same gene, which could un-
mask the heterozygous effects of a GJB3 point mutation
and harm gene function. The high incidence of DSPP
variants we found in category III (Table 1) is unlikely to
be caused by platform-specific errors, because we didn’t
find similar results in other batches of samples we proc-
essed (unpublished data). Those samples included more
than 1000 patients diagnosed with sensorineural hearing
loss and about 800 normal-hearing control samples.
Recent advances in technology have provided powerful
tools for the detection and analysis of CNVs at either
the whole-genome level or for targeted loci. Commonly
used methods in previous studies are either array-based
or polymerase chain reaction (PCR) based methods.
So far, aCGH arrays have been the most widely used
method for identification of CNVs on the genomic scale.
In the aCGH method, the ratios of respective signal in-
tensities derived from the test to those of reference sam-
ples are compared to give a measure of the CNVs. The
major disadvantage of aCGH arrays is its poor resolution
of CNVs, which is generally much larger than the size of
a single exon as achieved in this work. Quantitative PCR
(qPCR) is another commonly used method for screening
targeted genomic regions for CNVs, which is especially
efficient in detecting CNVs at single loci. The qPCR
approach has the advantage of potentially avoiding inter-
ference of pseudogenes if amplification primers are care-
fully designed. However, major disadvantages of qPCR
detections are that (1) qPCR is unable to give precise in-
teger measurements of CNVs [17]; (2) it is unable to effi-
ciently process multiple loci/genes for CNV analysis in
one test. Recently, a new approach has been developed
by taking advantage of the depth of read coverage gener-
ated in the NGS data analysis of each base pair in the
targeted regions [9,18], which is similar to what was
used in this study. Most published methods on CNV de-
tections from NGS data are designed for examining
CNVs on the whole genome or whole exome scale, with
specific mathematical models applied in the algorithms
[9]. For example, JointSLM and ExoCNVTest are de-
signed to detect common CNVs shared among many
samples. CoNIFER and XHMM are made to detect rare
CNVs using population data. In our approach, we used
the average read-depth of samples hybridized together
for exons covered, which greatly reduced the variations
introduced by GC content, capture efficiency, and align-
ment biases (Figure 1). The optimal detection length for
CNVs also depends on the specific program used. Pindel
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than 300 bp. In contrast, most prior read-depth based
bioinformatic tools are used to identify large CNVs
(e.g., >10,000 bps). The resolution of our method of
detecting CNVs is the size of single exon, which varies
between about 100 to a few thousand bps. The average
size of targeted exons for the 80 deafness genes is
4491 bps (Additional file 1: Table S1). Drawbacks of our
approach include the inability to detect the breakpoints
in CNVs, as well as common CNVs presented in many
samples. We used the average coverage of targeted exons
of deafness genes as the basis to calculate CNVs in the
targeted regions. Another vulnerability is that the pres-
ence of pseudogenes may cause false CNV gain events.
Among the 27 genes that showed CNVs (Table 3), we
found that five of them have corresponding pseudogenes
(MTAP, MYO15A, OTOAn SOX2 and STRC), according
to database www.pseudogene.org. The CNV data of these
small group of genes (5 out of 80), especially those on
CNV gains including qPCR validation results, need to be
cautiously interpreted.
We are only at an early stage of understanding the
combined effects of CNVs and mutations in the deafness
genes, especially about polymorphisms in CNVs in the
normal hearing control subjects. Similar to single nu-
cleotide polymorphisms (SNPs), most CNVs represent
benign copy number polymorphisms, and past studies
show that many of them have a population frequency of
>1% [14,19]. Deleterious CNVs include homozygous de-
letions of coding exons, which disrupt protein functions,
and therefore are highly likely to cause deafness. The
meaning of CNV gains, however, is more complicated to
interpret. Nonetheless, this work has demonstrated that
genetic causes of deafness could be found in a higher
percentage of patients when considering a combined
analysis of both DNA sequence variations and CNVs.
Conclusions
We investigated how CNVs in 80 known deafness genes
may result in deafness. Data presented in this paper sug-
gest that CNVs are a major type of structural variation,
which affect the function of genes known to be essential
for normal hearing, and thus play a significant role in
causing deafness. Among 79 sporadic cases clinically di-
agnosed with sensorineural hearing loss, we identified
both disease-causing DNA sequence mutations that were
previously reported, and novel CNV gains and losses in
27 deafness genes. These CNVs included homozygous
deletions, which may directly give rise to deleterious ef-
fects on protein functions known to be essential for hear-
ing, as well as heterozygous deletions and CNV gains,
which when compounded with sequence mutations in
deafness genes could potentially harm gene functions
known to be essential for hearing. The data provided hereserve as a basis to explain how CNVs could disrupt nor-
mal functions of deafness genes. With further accumula-
tion of more diverse types of samples, the analysis in
CNVs may significantly expand our understanding about
how combined DNA sequence and structural mutations
cause deafness in humans, and ultimately could help to
better explain the genetic causes of sensorineural hearing
loss in patients.
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